Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Stephanie SmiddyOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04127721 | Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | withdrawn | Phase 2 | 0 | Alain AlgaziOTHER | 0 | Oct 26, 2020 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03972046 | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | withdrawn | Phase 2 | 0 | TriHealth Inc.OTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT00226746 | Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer | withdrawn | Phase 2 | 0 | New York Presbyterian Brooklyn Methodist HospitalOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | withdrawn | Phase 2 | 0 | John M. BuattiOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 7, 2020 | clinicaltrials |
| NCT04392128 | Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)(HYACINTHE) | withdrawn | Phase 2 | 0 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | withdrawn | Phase 2 | 0 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2020 | clinicaltrials |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT03126461 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma(PIVOT-RCC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT00004878 | Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2020 | clinicaltrials |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS | withdrawn | Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02263898 | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02547948 | CD19-targeting CAR T Cells for B Cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT02575261 | CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT03252171 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT04406610 | CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 0 | Jul 16, 2020 | clinicaltrials |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 7, 2020 | clinicaltrials |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04016116 | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Loma Linda UniversityOTHER | 1 | Apr 30, 2020 | clinicaltrials |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia(CyFi2) | withdrawn | Phase 2 | 0 | AVEO Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial(DARALLO) | withdrawn | Phase 2 | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT03986086 | MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | withdrawn | Phase 1 / Phase 2 | 0 | Nelson ChaoOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 12, 2020source: clinicaltrials